Meningococcal Vaccine Market is predicted to procure USD 4.19 Bn by 2026, grow at a CAGR of 9.5%
As per the report published by Allied Market Research, the global Meningococcal Vaccine Industry garnered $1.93 billion in 2018, and is projected to garner $4.19 billion by 2026, witnessing a CAGR of 9.5% from 2019 to 2026. The study analyzes the important strategies, drivers, competition, market dynamics, size, and important investment regions.
Increasing Incidence of Meningococcal Diseases: Meningococcal diseases, caused by the bacteria Neisseria meningitidis, can lead to severe infections such as meningitis and septicemia. The rising incidence of these diseases, particularly among children and adolescents, has created a significant demand for meningococcal vaccines.
Growing Emphasis on Immunization Programs: Governments and healthcare organizations across the globe are increasingly focusing on immunization programs to prevent the spread of infectious diseases. Meningococcal vaccines are an integral part of these programs, leading to increased vaccination rates and market growth.
Introduction of New Vaccines: Several new vaccines targeting different serogroups of Neisseria meningitidis have been introduced in recent years. These vaccines offer broader coverage against multiple strains of the bacteria, enhancing their effectiveness and driving market growth.
Expansion in Developing Countries: Meningococcal diseases are prevalent in both developed and developing countries. However, there is an increasing focus on expanding vaccination programs in developing regions to address the high disease burden. This expansion is driving market growth and creating opportunities for vaccine manufacturers.
Technological Advancements: The development of advanced vaccine technologies, such as conjugate vaccines and recombinant vaccines, has improved the efficacy and safety of meningococcal vaccines. These technological advancements have further contributed to market growth.
Request Sample Copy of the Report:
Increasing Incidence of Meningococcal Diseases: Meningococcal diseases, such as meningitis and septicemia, continue to pose a significant public health threat globally. The rising incidence of these diseases, particularly in certain regions or population groups, drives the demand for meningococcal vaccines.
Government Immunization Programs: Governments worldwide are implementing robust immunization programs to prevent the spread of infectious diseases. Meningococcal vaccines are an essential component of these programs, leading to increased vaccination coverage and market demand.
Expanded Vaccine Recommendations: Public health organizations, such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), continually update and expand their recommendations for meningococcal vaccination. These recommendations drive the adoption of meningococcal vaccines in targeted populations, further fueling market growth.
Technological Advancements: Advances in vaccine technologies have improved the efficacy and safety of meningococcal vaccines. The development of conjugate vaccines and recombinant vaccines, for example, has enhanced immune response and broadened the coverage against different serogroups of Neisseria meningitidis. Technological advancements play a significant role in driving market growth.
- Conjugate Vaccines: Conjugate vaccines are the most common type of meningococcal vaccines available. They are formulated by attaching the polysaccharide antigen from the Neisseria meningitidis bacteria to a carrier protein. Examples include MenACWY (quadrivalent), MenB (bivalent), and MenACWY-CRM (quadrivalent).
- Polysaccharide Vaccines: Polysaccharide vaccines contain purified capsular polysaccharides from different serogroups of Neisseria meningitidis. They provide protection against specific serogroups, such as MenA, MenC, MenW, and MenY.
- Hospitals & Clinics: Vaccines distributed through hospitals, clinics, and healthcare facilities.
- Retail Pharmacies: Vaccines available through retail pharmacies for direct purchase or administration by healthcare professionals.
- Online Pharmacies: Vaccines distributed and sold through online pharmacy platforms.
- North America: Includes the United States and Canada.
- Europe: Includes countries in Western Europe, Eastern Europe, and the European Union.
- Asia Pacific: Includes countries such as China, India, Japan, and Australia.
- Latin America: Includes countries in Central and South America.
- Middle East & Africa: Includes countries across the Middle East and Africa region.
Request for Customization –
Regional Growth Dynamics:
North America accounted for the highest share, holding nearly half of the total share in 2018, and is estimated to maintain its dominant share during the forecast period. On the other hand, the Asia-Pacific region is also anticipated to manifest the fastest CAGR of 14.7% from 2019 to 2026. The market also analyses regions including Europe, North America, and LAMEA.
- Microsoft Corporation
- NVIDIA Corporation
- Data4Cure, Inc.
- Thermo Fisher Scientific
- SOPHiA GENETICS
- FDNA INC.
- Engine Biosciences Pte. Ltd.
- Fabric Genomics
- Verge Genomics
- Lifebit Biotech Ltd.
- Expanded Indication for MenB Vaccine: In recent years, there have been significant developments in the MenB (serogroup B) vaccine. One notable development is the expansion of the indication for MenB vaccines to include broader age groups. Previously, MenB vaccines were primarily recommended for adolescents and young adults at increased risk of meningococcal disease. However, regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have now extended the indication to include infants and children, allowing for broader protection against serogroup B meningococcal disease across various age groups.
- Introduction of New Generation Meningococcal Vaccines: There have been advancements in the development of next-generation meningococcal vaccines, particularly those targeting multiple serogroups (e.g., MenACWY) and innovative vaccine platforms. These new vaccines offer improved protection against a broader range of meningococcal strains, providing enhanced immunity and potentially reducing the need for multiple separate vaccinations. Furthermore, newer vaccine technologies, such as protein-based subunit vaccines and recombinant vaccines, have shown promise in clinical trials, offering potential advantages in terms of immunogenicity, safety, and manufacturing scalability.
Get an access to the library of reports at any time from any device and anywhere. For more details, follow the
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
- The Wire Times